Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04967989 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clarifying the Optimal Application of SLT Therapy Trial

Study acronym: COAST
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contacts updated at 5 of 29 sites Publications: 1 to 2v14 Show 1 more changeShow less
    • Publications: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  2. Phase: Not applicable to Phase 3v13
  3. Site details revised at 6 of 29 sitesv12
  4. Study sites: 30 to 29 Secondary endpoints: details revised at 1 of 3 entriesv11 Show 1 more changeShow less
    • Secondary endpoints: details revised at 1 of 3 entries
  5. Lead sponsor: West Virginia University to University of Pittsburgh Study sites revised (30) · Collaborators: 1 to 2v10 Show 2 more changesShow less
    • Study sites revised (30)
    • Collaborators: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

Show 8 earlier versionsHide 8 earlier versions
  1. Eligibility criteria expanded, about 8 words Study arms: 3 to 4v9 Show 1 more changeShow less
    • Study arms: 3 to 4

    See this version in full on ClinicalTrials.gov ↗

  2. Phase: Phase 3 to Not applicable Study arms: 4 to 3v8 Show 1 more changeShow less
    • Study arms: 4 to 3
  3. Enrollment target: 640 to 790 Site details revised at 10 of 30 sitesv7 Show 1 more changeShow less
    • Site details revised at 10 of 30 sites
  4. Primary endpoints revised (2) Eligibility criteria shortened, about 15 words · Site details revised at 30 of 30 sitesv6 Show 2 more changesShow less
    • Eligibility criteria shortened, about 15 words
    • Site details revised at 30 of 30 sites

    See this version in full on ClinicalTrials.gov ↗

  5. Eligibility criteria expanded, about 48 words Site details revised at 6 of 30 sitesv5 Show 1 more changeShow less
    • Site details revised at 6 of 30 sites

    See this version in full on ClinicalTrials.gov ↗

  6. Study sites: 19 to 30v4
  7. Primary completion date: Jun 2027 to Jun 30, 2027 Completion date: Aug 2027 to Aug 31, 2027 · Start date: Sep 22, 2021 to Sep 7, 2021v3 Show 2 more changesShow less
    • Completion date: Aug 2027 to Aug 31, 2027
    • Start date: Sep 22, 2021 to Sep 7, 2021
  8. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 19 · Start date changed from estimate of Sep 2021 to Sep 22, 2021v2 Show 2 more changesShow less
    • Study sites: 1 to 19
    • Start date changed from estimate of Sep 2021 to Sep 22, 2021
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Trial Details
NCT Number NCT04967989
Lead Sponsor University of Pittsburgh
Collaborators: National Eye Institute (NEI), West Virginia University
Conditions Glaucoma and Ocular Hypertension
Enrollment 790 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov